SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Lincoln Pharmaceuticals informs about outcome of board meeting

25 May 2023 Evaluate
Further to letter dated May 15, 2023 and pursuant to Regulation 30 and 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (SEBI Listing Regulations), Lincoln Pharmaceuticals has informed that the Board of Directors of the Company at its meeting held today i.e. on Thursday, May 25, 2023, have considered/ approved/ recommended, the followings: The Audited Financial Results (Standalone and Consolidated) of the Company for the quarter and year ended on March 31, 2023 along with the reports of auditors thereon. It has declared that the aforesaid audit reports are with unmodified opinion. The copies of the said financial results, declaration and auditor’s reports are enclosed. In terms of Regulation 47 of the Listing Regulations, the Company will publish an extract of audited standalone and consolidated financial results for the quarter and year ended on March 31, 2023. The audited financial results (standalone and consolidated) will be available at Company's website www.lincolnQharma.com; Recommended a dividend of Rs 1.50 (i.e. 15% per share) per equity share of face value of Rs 10 for the year ended March 31, 2023, for approval of the members at the ensuring annual general meeting (AGM) of the Company; Approved the resignation tendered by Anand A. Patel (DIN: 00103316), Whole Time Director of the Company from the position of Whole Time Director as well as Director of the Company to be made effective from May 25, 2023 after the closure of business hours. The details under Regulation 30 of SEBI (LODR) Regulations will be submitted separately. 

The above information is a part of company’s filings submitted to BSE.

Lincoln Pharma Share Price

672.25 -9.85 (-1.44%)
06-May-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1850.40
Dr. Reddys Lab 1310.50
Cipla 1365.25
Zydus Lifesciences 939.10
Lupin 2442.35
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×